Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET)
Immunological fitness, assessed by an anti-adenoviral specific antibody response and higher levels of activated CD8+ NKT-like cells after Delta-24-RGD treatment, may have utility as an early surrogate of a robust systemic immune response that correlates with long-term survival.
Authors
- Juan Pardellas Fueyo
- Thiagarajan Venkataraman (ORCID: https://orcid.org/0000-0003-0921-6345)
- F. Lang
- James P. Long
- S. Singh
- Frank Tufaro
- J. Weinberg
- Nam D. Tran (ORCID: https://orcid.org/0000-0003-0707-7580)
- Candelaria Gomez-Manzano
- Lynette M. Phillips
- PJ Anand
- Sujit Prabhu
- Deep Singh
- H. Benjamin Larman
- Chibawanye I. Ene
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Johns Hopkins University Applied Physics Laboratory (US)
- Moffitt Cancer Center (US)
- DNAtrix (United States) (US)
- Johns Hopkins Hospital (US)
- Neoleukin Therapeutics (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3566
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00